TY - JOUR T1 - EGFR exon in lung cancer: Survival predictors? JF - European Respiratory Journal JO - Eur Respir J VL - 40 IS - Suppl 56 SP - P4169 AU - Inês Ladeira AU - Ana Antunes AU - Carla Ribeiro AU - Ana Barroso AU - Sara Conde AU - Barbara Parente Y1 - 2012/09/01 UR - http://erj.ersjournals.com/content/40/Suppl_56/P4169.abstract N2 - EGFR mutations are associated with sensitivity to tyrosine kinase inhibitors(TKI) in patients with NSCLC.Studies point to different outcome to TKI treatment according to exon mutation.Aim:Understand how different EGFR mutations predict TKI response and affect survival.Methods: Records review of NSCLC patients with EGFR study(2006-2011). Epidemiological,clinical and outcome information was analyzed using SPSS19.0(p<0.05).Results: Of 409 patients studied 53 were EGFR-positive. After exclusion of 1 drug-resistant patient(exon20) and patients who did not use TKI or had TKI as 1st therapeutic,22 patients were considered-50%male,67.5±9.8y,59.1%non-smokers.Progression-free survival(PFS) was better in exon 19 mutations(p0.04). Survival after TKI(STKI) was better in 18 and 19 mutated patients (no statistical difference-p0.06).View this table:In non-surgical stages(72.8%), exon 19 mutated patients had better global survival(GS),STKI and PFS than others (p>0.05).View this table:Stages IIIB/IVAssociating patients with exons 18 and 20(described as less predictive of therapeutic outcome) GS29.1, STKI12.2 and PFS8.6 months, all higher than values found for exon21(p>0.05).Conclusions: Exon 19 mutation confered better prognosis to patients treated with TKI. Exons 18 and 20(22,7%) were not associated with worse prognosis than exon21. Although this is a small group we believe that is worth to maintain analysis of the 4 exon mutation. ER -